{"DataElement":{"publicId":"7150624","version":"1","preferredName":"Disease Progression Or Disease Transformation Difference Myeloproliferative Neoplasm Or Acute Myeloid Leukemia Subtype Classification Type","preferredDefinition":"A description of the myeloproliferative neoplasm or acute myeloid leukemia subtype after transformation.","longName":"7150569v1.0:7150601v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7150569","version":"1","preferredName":"Disease Progression Or Disease Transformation Difference Myeloproliferative Neoplasm Or Acute Myeloid Leukemia Subtype","preferredDefinition":"The worsening of a disease over time._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A conversion from one disease diagnosis to another, which may be considered a progression to a worsening state._The quality of being unlike or dissimilar._A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)_An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification)._A group forming a type within a larger type.","longName":"7204253v1.0:7150567v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"7204253","version":"1","preferredName":"Disease Progression Or Disease Transformation Difference","preferredDefinition":"The worsening of a disease over time.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A conversion from one disease diagnosis to another, which may be considered a progression to a worsening state.:The quality of being unlike or dissimilar.","longName":"C17747:C37998:C123583:C46003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Transformation","conceptCode":"C123583","definition":"A conversion from one disease diagnosis to another, which may be considered a progression to a worsening state.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Difference","conceptCode":"C46003","definition":"The quality of being unlike or dissimilar.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0FBC2DC-01D9-4832-E053-F662850AB482","latestVersionIndicator":"Yes","beginDate":"2020-03-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-03-16","modifiedBy":"ONEDATA","dateModified":"2020-03-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7150567","version":"1","preferredName":"Myeloproliferative Neoplasm Or Acute Myeloid Leukemia Subtype","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008):An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).:A group forming a type within a larger type.","longName":"C4345:C37998:C3171:C25696","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Subtype","conceptCode":"C25696","definition":"A group forming a type within a larger type.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D25A5CF-A07B-64BA-E053-F662850AF071","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D25A5CF-A08C-64BA-E053-F662850AF071","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"MALUMK","dateModified":"2020-12-03","changeDescription":"Released. 12/03/2020 KMM; Released. 11/11/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7150601","version":"1","preferredName":"Myeloproliferative Neoplasm Or Acute Myeloid Leukemia Classification Type","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008_An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification)._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics._Type; a subdivision of a particular kind of thing.","longName":"7150601v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Post-polycythemic myelofibrosis","valueDescription":"Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase","ValueMeaning":{"publicId":"5589177","version":"1","preferredName":"Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase","longName":"5589177","preferredDefinition":"Progression of polycythemia vera characterized by decreased erythropoiesis and granulopoiesis, reticulin and collagen fibrosis of the bone marrow, leucoerythroblastic reaction in the peripheral blood, poikilocytosis, tear-drop shaped red blood cells, and splenomegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase","conceptCode":"C41233","definition":"Progression of polycythemia vera characterized by decreased erythropoiesis and granulopoiesis, reticulin and collagen fibrosis of the bone marrow, leucoerythroblastic reaction in the peripheral blood, poikilocytosis, tear-drop shaped red blood cells, and splenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42EB656D-4036-53A3-E053-F662850A238D","latestVersionIndicator":"Yes","beginDate":"2016-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D2644D0-0963-6FF6-E053-F662850AE0BB","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"},{"value":"Post-essential thrombocythemic myelofibrosis","valueDescription":"Myelofibrosis Transformation in Essential Thrombocythemia","ValueMeaning":{"publicId":"5589179","version":"1","preferredName":"Myelofibrosis Transformation in Essential Thrombocythemia","longName":"5589179","preferredDefinition":"Myelofibrosis that develops in a patient with history of essential thrombocythemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post-Essential Thrombocythemia Myelofibrosis","conceptCode":"C126806","definition":"Myelofibrosis that develops in a patient with history of essential thrombocythemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42EB656D-405C-53A3-E053-F662850A238D","latestVersionIndicator":"Yes","beginDate":"2016-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D2644D0-0978-6FF6-E053-F662850AE0BB","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"},{"value":"Transformed to AML","valueDescription":"Conversion Acute Myeloid Leukemia","ValueMeaning":{"publicId":"3927451","version":"1","preferredName":"Conversion Acute Myeloid Leukemia","longName":"3927451","preferredDefinition":"The act of changing the nature, form, function, or purpose of something to another.: A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Conversion","conceptCode":"C52566","definition":"The act of changing the nature, form, function, or purpose of something to another.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96A8E65-4091-B964-E040-BB89AD437DDF","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D25F025-0233-06D8-E053-F662850AC9B2","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7150600","version":"1","preferredName":"Myeloproliferative Neoplasm Or Acute Myeloid Leukemia Classification Type","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008):An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).:A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.:Something distinguishable as an identifiable class based on common qualities.","longName":"7150600v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D25F025-00D6-06D8-E053-F662850AC9B2","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D25F025-00E7-06D8-E053-F662850AC9B2","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"MALUMK","dateModified":"2020-11-11","changeDescription":".Released 11/11/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"TDIS_MPN_mpn_AML_pst_trans_ty","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the myeloproliferati","type":"Preferred Question Text","description":"What was the myeloproliferative neoplasm or acute myeloid leukemia subtype after transformation?","url":null,"context":"NHLBI"},{"name":"Specify the MPN subtype or AML after transformation","type":"Alternate Question Text","description":"Specify the MPN subtype or AML after transformation","url":null,"context":"NHLBI"},{"name":"Specify the MPN subtype or AML after transformation","type":"Application Standard Question Text","description":"Specify the MPN subtype or AML after transformation","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D262AEE-0B57-65CF-E053-F662850A4099","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"MALUMK","dateModified":"2020-11-11","changeDescription":"Released. 11/11/2020 KMM; System generated def displayed as alt def. System generated def displayed as alt def. 03/16/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}